Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Pacific Research Partners LLC

Neither a doctor nor a teaching hospital

Research payments

$1,941,801

303 payments

Through program year 2025, Pacific Research Partners LLC is reported as receiving $1,941,801 in research payments, across 303 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $28,081 17
2024 Research $22 1
2023 Research $11,841 6
2022 Research $56,227 5
2021 Research $346,521 81
2020 Research $733,274 99
2019 Research $765,835 94

Breakdown

Who paid Research payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $577,633 69 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $437,662 15 payments
  3. ACADIA Pharmaceuticals Inc $210,459 29 payments
  4. Janssen Research & Development, LLC $117,976 39 payments
  5. Allergan Inc. $86,624 21 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $71,695 6 payments
  7. Eli Lilly and Company $68,561 18 payments
  8. Sage Therapeutics, Inc. $62,491 21 payments
  9. Corcept Therapeutics $51,700 11 payments
  10. Tolmar, Inc. $51,165 10 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $540,861 56 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $364,820 5 payments
  3. Acp-103-059 $127,537 11 payments
  4. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $76,975 24 payments
  5. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $76,124 19 payments
  6. Adjunctive Computerized Cognitive Training CCT $63,772 5 payments
  7. A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus $51,499 3 payments
  8. Tol3010b $51,165 10 payments
  9. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Sage-217 in the Treatment of Adult Subjects With Major Depressive Disorder $42,441 10 payments
  10. Acp-103-055 $41,833 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record